Physician profile
Mohammad B Anwer
NPI 1285643445
$375.41
in general payments reported to CMS, 2019-2025
12 companies · $265 in 2025
The $265 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $23.81 · 2021: $11.55 · 2022: $18.72 · 2024: $56.44 · 2025: $265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $321.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $86.97 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $38.52 | 2025 | Dupixent |
| Boston Scientific Corporation | $33.91 | 2021-2024 | |
| Intercept Pharmaceuticals, INC. | $30.14 | 2025 | |
| Celltrion USA INC. | $28.08 | 2025 | Vegzelma |
| Enterra Medical, INC. | $27.09 | 2025 | |
| Janssen Biotech, INC. | $26.67 | 2025 | Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.17 | 2025 | Ofev |
| Cook Medical LLC | $23.81 | 2020 | |
| Abbvie INC. | $19.04 | 2024 | |
| Evoke Pharma, INC. | $18.72 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.29 | 2025 | Eohilia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Anwer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.